NCT02418481View on ClinicalTrials.gov

Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Breast Cancer
Interventions
BIOLOGICAL

DC-CIK

DC-CIK cells will be used against tumor cells.

BIOLOGICAL

γδ T Cell

γδ T cells will be used against breast tumor.

BIOLOGICAL

Combination

γδ T/DC-CIK cells will be used against breast tumor.

Trial Locations (1)

510000

Biological treatment center in Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Jinan University Guangzhou

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02418481 - Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-) | Biotech Hunter | Biotech Hunter